FDA Approves Amgen ' s Parsabiv (etelcalcetide) for Secondary Hyperparathyroidism in Adult Patients on Hemodialysis

THOUSAND OAKS, Calif., Feb. 7, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Parsabiv (etelcalcetide) for the treatment of secondary hyperparathyroidism (HPT) in adult patients...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news